THE COMPATIBILITY PROBLEM
Retatrutide and thiamine formulation compatibility
A peptide and a small water-soluble vitamin do not naturally share a comfortable liquid environment. Each brings its own stability optimum for pH, ionic strength and excipient composition; the peptide additionally carries aggregation and adsorption sensitivities, and thiamine carries pH-dependent degradation and light and oxidation sensitivities. Combining them is therefore an engineering programme, not a mixing instruction.
The named conflicts
- pH — each component’s chemical stability is pH-dependent, and the optima are not assumed to coincide; a shared liquid would force at least one component away from its preferred range.
- pI — near its isoelectric point a peptide’s solubility falls and aggregation risk rises, so the reconstituted environment must respect the peptide’s pI behaviour.
- Ionic strength — the salt environment influences peptide solubility, thiamine behaviour and the tonicity of the final preparation.
- Solubility — both layers must dissolve rapidly and completely in the same 0.5 mL, at the same time, without precipitation, visible particulates or excessive reconstitution time.
The architectural answer: separation in storage, reconciliation at activation
Reta-B1 does not store the two actives as one liquid. Inside the protected Lyoprester SS™ chamber, the retatrutide peptidic layer is frozen first and the supercooled thiamine layer is placed above it; the two are co-lyophilised as a dual-layer Peptourbillon™ — sharing the cycle and the cartridge but not a premixed solution. The compatibility question is thereby split in two: a physical question for storage (do the layers stay distinct?), and a chemical question for the seconds after activation (does one short-lived liquid form correctly?).
The second half belongs to P-EARLs™: the 0.5 mL reconstitution vehicle is being engineered specifically for this formulation to reconcile or neutralise pH-, pI-, ionic-strength- and solubility-related conflicts during rapid reconstitution. This is an engineering objective under evaluation. It is not claimed that all pH and pI conflicts have already been eliminated; that claim must wait for completed analytical data.
What this page deliberately omits
No manufacturing recipe, no sterile-production instructions and no excipient quantities appear on this site. Publishing compositional detail that has not been formally evaluated would be both scientifically premature and inconsistent with the site’s evidence discipline. The programme-level view — what must be measured, and why — is on the testing programme page.